Do you want to read an article? Please log in or register.
Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: the IM-UNITI trial
Inflammatory Bowel Disease
COMMENTED
Related content
Inflammatory Bowel Disease
IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease
J Crohns Colitis.
Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S
doi: 10.1093/ecco-jcc/jjz110.
RECOMMENDED
Inflammatory Bowel Disease
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Gastroenterology.
Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J
doi: 10.1053/j.gastro.2020.01.047.
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Cannabis for the treatment of Crohn's disease
Cochrane Database Syst Rev.
Kafil TS, Nguyen TM, MacDonald JK, Chande N
doi: 10.1002/14651858.
Inflammatory Bowel Disease
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: The Scottish ustekinumab Cohort
J Gastroenterol Hepatol
Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Lam W, Saunders J, Kelly C, Gaya DR, Jafferbhoy HM, Macdonald JC, Seenan JP, Mowat C, Naismith GD, Potts LF, Sutherland DI, Watts DA, Arnott ID, Bain G, Jones GR, Lees CW
doi: 10.1111/jgh.15390
Inflammatory Bowel Disease
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
J Crohns Colitis
Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR
doi: 10.1093/ecco-jcc/jjab093
Inflammatory Bowel Disease
Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort Minimally Invasive Gastrointestinal Surgery
Inflamm Bowel Dis.
Weaver KN, Gregory M, Syal G, Hoversten P, Hicks SB, Patel D, Christophi G, Beniwal-Patel P, Isaacs KL, Raffals L, Deepak P, Herfarth HH, Barnes EL
doi: 10.1093/ibd/izy302.
Inflammatory Bowel Disease
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn's Disease
Gastroenterology.
Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer S, Feagan BG, Ghosh S, Sandborn WJ
doi: 10.1053/
Inflammatory Bowel Disease
Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study
BMC Gastroenterol.
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO, Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators., European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP)
doi: 10.1186/s12876-019-0992-2.